Eli Lilly (LLY) Accumulated Depreciation & Amortization (2009 - 2025)

Eli Lilly has reported Accumulated Depreciation & Amortization for 17 years, with the latest figure at $2.0 billion in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 13.02% year-over-year to $2.0 billion; the trailing twelve-month figure through Dec 2025 stood at $2.0 billion (up 13.02% YoY), and the FY2025 full-year result was $2.0 billion, up 13.02% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $2.0 billion, up from $470.0 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $2.0 billion in Q4 2025, with the low at $350.3 million in Q1 2021.
• Historically, Accumulated Depreciation & Amortization has averaged $952.0 million across 5 years, with a median of $799.8 million in 2022.
• Annual changes were most pronounced in 2021 — Accumulated Depreciation & Amortization gained 28.03% — and 2025, when it slumped 63.33%.
• Eli Lilly's Accumulated Depreciation & Amortization stood at $1.5 billion in 2021, then retreated by 1.62% to $1.5 billion in 2022, then climbed by 0.3% to $1.5 billion in 2023, then gained by 15.72% to $1.8 billion in 2024, then climbed by 13.02% to $2.0 billion in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $2.0 billion (Q4 2025), $470.0 million (Q3 2025), and $478.5 million (Q2 2025), per Business Quant data.